CREDELIO- antiparasitic for cats - 3 tablets
ELANCO
€ 55.00
For the treatment of flea and tick infestation in cats.
The veterinary medicinal product has immediate and persistent elimination activity for up to a month against fleas (Ctenocephalides felis and C. canis) and ticks (Ixodes ricinus).
Fleas and ticks must attach to the host and begin to feed in order to be exposed to the active substance.
The veterinary medicinal product can be used as part of a therapeutic strategy in the control of allergic dermatitis caused by flea saliva.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
The parasites must begin to feed in order to be exposed to the lotilaner; Consequently, the risk of transmission of diseases through parasites cannot be completely ruled out.
Acceptable levels of efficacy may not be achieved if the veterinary medicinal product is not administered with food or within 30 minutes after feeding.
Due to insufficient data to support efficacy against ticks in young cats, this product is not recommended for the treatment of ticks in kittens aged 5 months or less.
Safety and efficacy data were studied in cats aged 8 weeks and over, with a body weight of 0.5 kg or more. Therefore, the use of this veterinary medicinal product in kittens under 8 weeks of age or with a body weight of less than 0.5 kg should be considered based on a risk / benefit assessment by the responsible veterinarian.
Special precautions to be taken by the person administering the veterinary medicinal product to animals. Wash your hands after handling the product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Laboratory studies in rats did not produce any evidence of teratogenic effects or any other adverse effects on reproductive capacity in males and females. The safety of the veterinary medicinal product has not been established in pregnant or lactating cats. Use only in accordance with the risk / benefit assessment performed by the responsible veterinarian.
During clinical trials, no interactions were observed between Credelio chewable tablets and routine veterinary medicinal products.
Lotilaner, a pure enantiomer of the isoxazoline class, is active against fleas (Ctenocephalides felis and Ctenocephalides canis), as well as ticks (Ixodes ricinus).
Lotilaner is a potent inhibitor of chlorine ion channels regulated by gamma-aminobutyric acid (GABA), causing the rapid death of ticks and fleas. In in vitro studies, activity against some arthropod species was not affected by resistance to organochlorine compounds (cyclodee, eg dieldrin), phenylpyrazoles (eg fipronil), neonicotinoids (eg imidacloprid), formamidines (eg , amitraz) and pyrethroids (eg cypermethrin).
For fleas, the installation of efficacy occurs within 12 hours of fixation and lasts one month after administration of the product. Fleas existing on the animal before administration are eliminated within 8 hours.
For ticks, the installation of efficacy occurs within 24 hours of fixation and lasts one month after administration of the product. Ticks on the animal before administration are removed within 18 hours.
The veterinary medicinal product eliminates fleas that exist on cats and have recently hatched, before they can lay eggs. Therefore, the product interrupts the life cycle of fleas and prevents contamination of the environment with fleas in the areas where cats had access.
After oral administration, lotilaner is absorbed immediately and the maximum plasma concentration is reached in 4 hours. Lotilaner is approximately 10 times more bioavailable when co-administered with food. The half-life until elimination is about 4 weeks (harmonic average). This long half-life until elimination ensures effective plasma concentrations over the entire dose interval.
The main route of elimination is by biliary excretion, renal excretion being the secondary route of elimination (less than 10% of the dose). Lotilaner is metabolized to a small extent into several hydrophilic compounds that can be detected in feces and urine.
The veterinary medicinal product has immediate and persistent elimination activity for up to a month against fleas (Ctenocephalides felis and C. canis) and ticks (Ixodes ricinus).
Fleas and ticks must attach to the host and begin to feed in order to be exposed to the active substance.
The veterinary medicinal product can be used as part of a therapeutic strategy in the control of allergic dermatitis caused by flea saliva.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
The parasites must begin to feed in order to be exposed to the lotilaner; Consequently, the risk of transmission of diseases through parasites cannot be completely ruled out.
Acceptable levels of efficacy may not be achieved if the veterinary medicinal product is not administered with food or within 30 minutes after feeding.
Due to insufficient data to support efficacy against ticks in young cats, this product is not recommended for the treatment of ticks in kittens aged 5 months or less.
Safety and efficacy data were studied in cats aged 8 weeks and over, with a body weight of 0.5 kg or more. Therefore, the use of this veterinary medicinal product in kittens under 8 weeks of age or with a body weight of less than 0.5 kg should be considered based on a risk / benefit assessment by the responsible veterinarian.
Special precautions to be taken by the person administering the veterinary medicinal product to animals. Wash your hands after handling the product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Laboratory studies in rats did not produce any evidence of teratogenic effects or any other adverse effects on reproductive capacity in males and females. The safety of the veterinary medicinal product has not been established in pregnant or lactating cats. Use only in accordance with the risk / benefit assessment performed by the responsible veterinarian.
During clinical trials, no interactions were observed between Credelio chewable tablets and routine veterinary medicinal products.
Lotilaner, a pure enantiomer of the isoxazoline class, is active against fleas (Ctenocephalides felis and Ctenocephalides canis), as well as ticks (Ixodes ricinus).
Lotilaner is a potent inhibitor of chlorine ion channels regulated by gamma-aminobutyric acid (GABA), causing the rapid death of ticks and fleas. In in vitro studies, activity against some arthropod species was not affected by resistance to organochlorine compounds (cyclodee, eg dieldrin), phenylpyrazoles (eg fipronil), neonicotinoids (eg imidacloprid), formamidines (eg , amitraz) and pyrethroids (eg cypermethrin).
For fleas, the installation of efficacy occurs within 12 hours of fixation and lasts one month after administration of the product. Fleas existing on the animal before administration are eliminated within 8 hours.
For ticks, the installation of efficacy occurs within 24 hours of fixation and lasts one month after administration of the product. Ticks on the animal before administration are removed within 18 hours.
The veterinary medicinal product eliminates fleas that exist on cats and have recently hatched, before they can lay eggs. Therefore, the product interrupts the life cycle of fleas and prevents contamination of the environment with fleas in the areas where cats had access.
After oral administration, lotilaner is absorbed immediately and the maximum plasma concentration is reached in 4 hours. Lotilaner is approximately 10 times more bioavailable when co-administered with food. The half-life until elimination is about 4 weeks (harmonic average). This long half-life until elimination ensures effective plasma concentrations over the entire dose interval.
The main route of elimination is by biliary excretion, renal excretion being the secondary route of elimination (less than 10% of the dose). Lotilaner is metabolized to a small extent into several hydrophilic compounds that can be detected in feces and urine.